144 related articles for article (PubMed ID: 38363819)
41. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
42. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
[TBL] [Abstract][Full Text] [Related]
43. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
44. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
45. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
46. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
47. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
48. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
49. Preparation of
Kameswaran M; Pandey U; Gamre N; Sarma HD; Dash A
Appl Radiat Isot; 2019 Jun; 148():184-190. PubMed ID: 30974402
[TBL] [Abstract][Full Text] [Related]
50. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
Fakih MG
Oncologist; 2018 Apr; 23(4):474-477. PubMed ID: 29330210
[TBL] [Abstract][Full Text] [Related]
51. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
Wege AK; Kirchhammer N; Kazandjian LV; Prassl S; Brandt M; Piendl G; Ortmann O; Fischer S; Brockhoff G
J Transl Med; 2020 Aug; 18(1):316. PubMed ID: 32799890
[TBL] [Abstract][Full Text] [Related]
52. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
[TBL] [Abstract][Full Text] [Related]
53. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
54. Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.
Gleeson JP; Keegan NM; Morris PG
Expert Opin Biol Ther; 2018 Mar; 18(3):251-262. PubMed ID: 29183167
[TBL] [Abstract][Full Text] [Related]
55. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
56. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
[TBL] [Abstract][Full Text] [Related]
57. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
[TBL] [Abstract][Full Text] [Related]
58. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
